Array BioPharma Recruits Pierre Fabre As European Partner

The ability of Pierre Fabre to compete in the near term against oncology heavyweights like Novartis and Roche was key to selecting the French company to commercialize and further develop Array BioPharma's MEK inhibitor binimetinib and BRAF inhibitor encorafenib in Europe and emerging markets.